Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)

NCT03401112 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03401112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03401112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2018
Completion date
August 28, 2020
Enrollment
100 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease